<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Crescent Biopharma, Inc. — News on 6ix</title>
<link>https://6ix.com/company/crescent-biopharma-inc</link>
<description>Latest news and press releases for Crescent Biopharma, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 27 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/crescent-biopharma-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d73fca51cc36e475330d62.webp</url>
<title>Crescent Biopharma, Inc.</title>
<link>https://6ix.com/company/crescent-biopharma-inc</link>
</image>
<item>
<title>Crescent Biopharma Announces Grants of Inducement Awards</title>
<link>https://6ix.com/company/crescent-biopharma-inc/news/crescent-biopharma-announces-grants-of-inducement-awards-1</link>
<guid isPermaLink="true">https://6ix.com/company/crescent-biopharma-inc/news/crescent-biopharma-announces-grants-of-inducement-awards-1</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology</description>
</item>
<item>
<title>Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/crescent-biopharma-inc/news/crescent-biopharma-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/crescent-biopharma-inc/news/crescent-biopharma-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>Established partnership with Kelun-Biotech expanding pipeline and accelerating combination strategy with CR-001, PD-1 x VEGF bispecific antibody, and multiple</description>
</item>
<item>
<title>Crescent Biopharma to Present at March Investor Conferences</title>
<link>https://6ix.com/company/crescent-biopharma-inc/news/crescent-biopharma-to-present-at-march-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/crescent-biopharma-inc/news/crescent-biopharma-to-present-at-march-investor-conferences</guid>
<pubDate>Mon, 23 Feb 2026 12:30:00 GMT</pubDate>
<description>WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in March: TD Cowen 46th Annual Health Care Conference, fireside chat on Monday, March 2, 2026 at 3:50 p.m. ET in Boston.Leerink Partners 2026 Global Healthcare Confere</description>
</item>
<item>
<title>Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors</title>
<link>https://6ix.com/company/crescent-biopharma-inc/news/crescent-biopharma-announces-first-patient-dosed-in-ascend-phase-12-clinical-trial-of-cr-001-for-the-treatment-of-advanced-solid-tumors</link>
<guid isPermaLink="true">https://6ix.com/company/crescent-biopharma-inc/news/crescent-biopharma-announces-first-patient-dosed-in-ascend-phase-12-clinical-trial-of-cr-001-for-the-treatment-of-advanced-solid-tumors</guid>
<pubDate>Wed, 18 Feb 2026 05:00:00 GMT</pubDate>
<description>ASCEND to evaluate CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types, including NSCLC and gastrointestinal and gynecological cancers in</description>
</item>
<item>
<title>Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026</title>
<link>https://6ix.com/company/crescent-biopharma-inc/news/crescent-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026</link>
<guid isPermaLink="true">https://6ix.com/company/crescent-biopharma-inc/news/crescent-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026</guid>
<pubDate>Thu, 05 Feb 2026 12:30:00 GMT</pubDate>
<description>WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York on Thursday, February 12, 2026 at 11:30 a.m. ET. A live webcast of the presentation will be available in the Inves</description>
</item>
<item>
<title>Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors</title>
<link>https://6ix.com/company/crescent-biopharma-inc/news/crescent-biopharma-announces-regulatory-clearances-of-ind-applications-for-cr-001-a-pd-1-x-vegf-bispecific-antibody-and-cr-003-an-itgb6-targeted-adc-for-the-treatment-of-solid-tumors</link>
<guid isPermaLink="true">https://6ix.com/company/crescent-biopharma-inc/news/crescent-biopharma-announces-regulatory-clearances-of-ind-applications-for-cr-001-a-pd-1-x-vegf-bispecific-antibody-and-cr-003-an-itgb6-targeted-adc-for-the-treatment-of-solid-tumors</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>CR-001 IND cleared by U.S. FDA; Phase 1/2 ASCEND global clinical trial to evaluate CR-001 in first-line and previously treated patients on track to initiate</description>
</item>
<item>
<title>Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics</title>
<link>https://6ix.com/company/crescent-biopharma-inc/news/kelun-biotech-and-crescent-biopharma-announce-strategic-partnership-to-develop-and-commercialize-novel-oncology-therapeutics-1</link>
<guid isPermaLink="true">https://6ix.com/company/crescent-biopharma-inc/news/kelun-biotech-and-crescent-biopharma-announce-strategic-partnership-to-develop-and-commercialize-novel-oncology-therapeutics-1</guid>
<pubDate>Thu, 04 Dec 2025 11:30:00 GMT</pubDate>
<description>Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets and China Collaboration designed to accelerate and expand the development of synergistic combinations with CR-001 and ADCs, including SKB105 CR-001 and SKB105 on track to enter Phase 1/2 monotherapy clinical trials in Q1 2026 with combination studies to follow CHENGDU, China and WALTHAM, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Sichuan Kelun-Bio</description>
</item>
<item>
<title>Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors</title>
<link>https://6ix.com/company/crescent-biopharma-inc/news/crescent-biopharma-announces-transformational-partnership-with-kelun-biotech-and-dollar185-million-private-placement-accelerating-and-expanding-global-pipeline-of-next-generation-therapeutics-for-solid-tumors</link>
<guid isPermaLink="true">https://6ix.com/company/crescent-biopharma-inc/news/crescent-biopharma-announces-transformational-partnership-with-kelun-biotech-and-dollar185-million-private-placement-accelerating-and-expanding-global-pipeline-of-next-generation-therapeutics-for-solid-tumors</guid>
<pubDate>Thu, 04 Dec 2025 05:00:00 GMT</pubDate>
<description>Partnership with Kelun-Biotech expands pipeline and accelerates combination strategy with CR-001, a PD-1 x VEGF bispecific antibody, and multiple</description>
</item>
<item>
<title>Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/crescent-biopharma-inc/news/crescent-biopharma-reports-third-quarter-2025-financial-results-and-recent-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/crescent-biopharma-inc/news/crescent-biopharma-reports-third-quarter-2025-financial-results-and-recent-business-highlights</guid>
<pubDate>Thu, 06 Nov 2025 12:30:00 GMT</pubDate>
<description>IND Submission for CR-001, a PD-1 x VEGF Bispecific Antibody, on Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors Advancing ADCs in the Pipeline, with IND Submission for CR-002 on Track for Mid-2026 WALTHAM, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced f</description>
</item>
<item>
<title>Crescent Biopharma to Present at November Investor Conferences</title>
<link>https://6ix.com/company/crescent-biopharma-inc/news/crescent-biopharma-to-present-at-november-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/crescent-biopharma-inc/news/crescent-biopharma-to-present-at-november-investor-conferences</guid>
<pubDate>Wed, 05 Nov 2025 12:30:00 GMT</pubDate>
<description>WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in November: Guggenheim 2nd Annual Healthcare Innovation Conference, fireside chat on Tuesday, November 11, 2025, at 8:00 a.m. ET in Boston.Stifel 2025 Healthcare Conference, firesid</description>
</item>
<item>
<title>Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting</title>
<link>https://6ix.com/company/crescent-biopharma-inc/news/crescent-biopharma-to-present-preclinical-data-for-cr-001-a-pd-1-x-vegf-bispecific-antibody-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/crescent-biopharma-inc/news/crescent-biopharma-to-present-preclinical-data-for-cr-001-a-pd-1-x-vegf-bispecific-antibody-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>CR-001 Demonstrated Cooperative Pharmacology and Robust Anti-Tumor Activity IND Submission for CR-001 On Track for Fourth Quarter of 2025 to Support</description>
</item>
<item>
<title>Crescent Biopharma to Present at September Investor Conferences</title>
<link>https://6ix.com/company/crescent-biopharma-inc/news/crescent-biopharma-to-present-at-september-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/crescent-biopharma-inc/news/crescent-biopharma-to-present-at-september-investor-conferences</guid>
<pubDate>Thu, 28 Aug 2025 11:30:00 GMT</pubDate>
<description>WALTHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in September: Cantor Global Healthcare Conference 2025, fireside chat on Thursday, September 4, 2025, at 1:00 p.m. ET in New York. Morgan Stanley 23rd Annual Global Healthcare Confer</description>
</item>
<item>
<title>Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/crescent-biopharma-inc/news/crescent-biopharma-reports-second-quarter-2025-financial-results-and-recent-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/crescent-biopharma-inc/news/crescent-biopharma-reports-second-quarter-2025-financial-results-and-recent-business-highlights</guid>
<pubDate>Thu, 31 Jul 2025 04:00:00 GMT</pubDate>
<description>Completed Merger with GlycoMimetics and Previously Announced $200 Million Private Financing Supporting Pipeline of Next Generation Therapeutics for Solid</description>
</item>
<item>
<title>Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer</title>
<link>https://6ix.com/company/crescent-biopharma-inc/news/crescent-biopharma-appoints-jan-pinkas-phd-as-chief-scientific-officer</link>
<guid isPermaLink="true">https://6ix.com/company/crescent-biopharma-inc/news/crescent-biopharma-appoints-jan-pinkas-phd-as-chief-scientific-officer</guid>
<pubDate>Tue, 08 Jul 2025 11:30:00 GMT</pubDate>
<description>Seasoned Leader Brings Deep Experience in Oncology Drug Development as Company Advances Portfolio of Next Generation Therapeutics for Solid Tumors WALTHAM, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced the appointment of Jan Pinkas, Ph.D., as chief scientific officer. Dr. Pinkas brings more than two decades of exp</description>
</item>
</channel>
</rss>